NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
IPO Year: 2017
Exchange: NASDAQ
Website: neurorxpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $18.00 | Buy | BTIG Research |